New freezing biopsy could make lung cancer diagnosis safer

NCT ID NCT04548830

Completed Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests whether a biopsy technique called transbronchial cryobiopsy is safer than the standard method for diagnosing lung cancer. About 100 adults with known or suspected lung cancer will undergo the procedure under general anesthesia. Researchers will track complications to see if this freezing-based approach reduces risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transbronchial cryobiopsy (a procedure using a freezing probe to take lung tissue samples)
What this could lead to: If successful, this could offer a safer and more effective way to diagnose lung cancer, reducing complications from standard biopsies.
What could go wrong: This is a small, early-phase study focused on safety, not treatment. The procedure may still carry risks like bleeding or lung collapse, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.